Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11113228 | 0.81 | MAOB (0.36) | MAOBALDH1A1MAPK1KMT2AAKT1 | |
| SCHEMBL1054915 | 0.81 | ALDH1A1 (0.37) | MAOBALDH1A1MAPK1KMT2A | |
| SCHEMBL11116397 | 0.80 | ALDH1A1 (0.35) | MAOBALDH1A1MAPK1KMT2AAKT1 | |
| SCHEMBL11114171 | 0.80 | ALOX15 (0.35) | MAOBALDH1A1MAPK1KMT2AAKT1 | |
| SCHEMBL11107207 | 0.79 | AKT1 (0.32) | MAOBALDH1A1MAPK1KMT2AAKT1 | |
| SCHEMBL1057779 | 0.76 | ERN1 (0.34) | MAOBALDH1A1MAPK1KMT2A | |
| SCHEMBL10801359 | 0.72 | MAOB (0.37) | MAOBALDH1A1MAPK1KMT2A | |
| SCHEMBL11107152 | 0.72 | LMNA (0.46) | ALDH1A1MAPK1 | |
| SCHEMBL1052862 | 0.69 | L3MBTL1 (0.43) | MAOBMAPK1 | |
| SCHEMBL12563136 | 0.68 | ALDH1A1 (0.40) | MAOBALDH1A1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872014-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1648455-A4 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20070032515-A1 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1648455-A2 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005009389-A2 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-0103173-A1 | Carbamic-acid esters, process and starting material for their preparation, parasiticides containing these esters as active products, as well as the use of such esters and agents in combating parasites | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032515-A1 | Anaplastic lymphoma kinase modulators and methods of use | ALK, MALT1, BCL6 | MAOB 3032/4885ALDH1A1 1285/4885MAPK1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.